Fig. 5: Co-delivery of CpG1826 enhanced the efficacy of NPmut/3M2e. | npj Vaccines

Fig. 5: Co-delivery of CpG1826 enhanced the efficacy of NPmut/3M2e.

From: Addressing unexpected bacterial RNA safety concerns of E. coli produced influenza NP through CpG loaded mutant

Fig. 5

Mice were immunized as shown in Fig.1A. NP-specific IgG (A) and M2e-specific IgG (B) were determined by ELISA (n = 5). NP-specific CD4+ T cells (C) and M2e-specific CD4+ T cells (D) were determined by activation-induced marker assay (n = 5). NP-specific CD8+ T cells (E) were determined by intracellular cytokine staining assay (n = 3). F NP- specific IgG and IgA in BALF (n = 5). G M2e-specific IgG and IgA in BALF (n = 5). Data are presented as mean ± S.D. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns, not significant (ANOVA). Mice (n = 5) were challenged with 5 × LD50 of A/PR/8/34 (H) and 2.75 × LD50 of A/SD/12/2019 (I) 2 weeks after the last immunization. Weight loss and survival rate were monitored daily for 14 days. Statistical significance of survival curves was determined by the log-rank (Mantel-Cox) test. H * between PBS and 3M2e/NPmut, ** between PBS and 3M2e/NPmut/CpG1826, * between 3M2e/NPmut and 3M2e/NPmut/CpG1826. I ns between PBS and 3M2e/NPmut, * between PBS and 3M2e/NPmut/CpG1826, ns between 3M2e/NPmut and 3M2e/NPmut/CpG1826.

Back to article page